Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 678 | 130 | 532 |
| Samples | 479 | 98 | 370 |
| Peptides | 379 | 70 | 308 |
Function
ADAMTS4 · ADAM metallopeptidase with thrombospondin type 1 motif 4
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of this family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The enzyme encoded by this gene lacks a C-terminal TS motif. The encoded preproprotein is proteolytically processed to generate the mature protease. This protease is responsible for the degradation of aggrecan, a major proteoglycan of cartilage, and brevican, a brain-specific extracellular matrix protein. The expression of this gene is upregulated in arthritic disease and this may contribute to disease progression through the degradation of aggrecan. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Feb 2016].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 368 amino-acid changes on canonical ENST00000367996 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADAMTS4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADAMTS4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 18/612 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 32/1390 2% |
| Melanoma | 13/210 6% | 43/1899 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 17/810 2% |
| Colorectal Carcinoma | 10/143 7% | 60/3239 2% |
| Gastric Carcinoma | 3/74 4% | 34/1809 2% |
| Other Solid Cancers | 2/94 2% | 22/1515 1% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Ewings Sarcoma | 1/63 2% | 3/262 1% |
| Ovarian Carcinoma | 2/109 2% | 10/998 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 17/2550 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 5/752 1% |
| Head and Neck Carcinoma | 3/85 4% | 10/1574 1% |
| Non-Cancerous | 1/104 1% | 6/830 1% |
| Pancreatic Carcinoma | 2/89 2% | 9/1611 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 13/2534 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Hepatocellular Carcinoma | 1/46 2% | 11/2210 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Glioma | 0/52 0% | 11/2127 1% |
| Prostate Carcinoma | 2/13 15% | 8/2105 0% |
Mutation Distribution
Where ADAMTS4 is mutated · all tissues, split by cell line vs tissue
How many mutations in ADAMTS4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 678 mutations in ADAMTS4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|